医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Jointly Announce Taiho’s Exercise of Its Option for an Exclusive License to Zimberelimab

Arcus Biosciences and Taiho Pharmaceutical Co., Ltd. Jointly Announce Taiho’s Exercise of Its Option for an Exclusive License to Zimberelimab (AB122) for Its Territories in Japan and Other Asian Countries

バイオテクノロジー ヘルスケア 病院 腫瘍学 臨床試験 製薬 遺伝学　 TimeLine: AB122Arcus Biosciences and Taiho Pharmaceutical Cofor Its Territories in Japan and Other Asian CountriesJointly Announce Taiho’s Exercise of Its Option for an Exclusive License to Zimberelimab

2020年02月26日